22 September 2022
Amazing news from ESMO – European Society for Medical Oncology‘s congress – these early Phase 1 Trial results suggest genetically engineered cancer-killing viruses could potentially offer hope to some patients where other forms of immunotherapy have not worked. Great job, The Institute of Cancer Research!
The engineered herpes RP2 virus injected directly into the tumours, multiplies inside cancer cells to burst them from within, but it also blocks a protein known as CTLA-4 – releasing the brakes on the immune system and increasing its ability to kill cancer cells.
Read more: ICR – Genetically modified herpes virus delivers one-two punch against advanced cancers